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Abstract
Background: Insulin-degrading enzyme (IDE) is the ubiquitously expressed enzyme responsible for insulin and
amyloid beta (Ab) degradation. IDE gene is located on chromosome region 10q23-q25 and exhibits a well-
replicated peak of linkage with Type 2 diabetes mellitus (T2DM). Several genetic association studies examined IDE
gene as a susceptibility gene for Alzheimer’s disease (AD), however with controversial results.
Methods: We examined associations of three IDE polymorphisms (IDE2, rs4646953; IDE7, rs2251101 and IDE9,
rs1887922) with AD, Ab42 plasma level and T2DM risk in the longitudinal Vienna Transdanube Aging (VITA) study
cohort.
Results: The upstream polymorphism IDE2 was found to influence AD risk and to trigger the Ab42 plasma level,
whereas the downstream polymorphism IDE7 modified the T2DM risk; no associations were found for the intronic
variant IDE9.
Conclusions: Based on our SNP and haplotype results, we delineate the model that IDE promoter and 3’
untranslated region/downstream variation may have different effects on IDE expression, presumably a relevant
endophenotype with disorder-specific effects on AD and T2DM susceptibility.
Background
Insulin degrading enzyme (IDE), also known as insuly-
sin, insulin protease or insulinase, is a 110 kDA zinc-
dependent metalloprotease of the M16A subfamily,
which is coded by a 122 kb spanning, ubiquitously
expressed gene on the distal region of the human chro-
mosome 10 q [1]. Apart from its primary target insulin,
IDE competitively hydrolyzes multiple proteins including
glucagon, atrial natriuretic factor, transforming growth
factor-a,a n db-endorphin amylin [2,3] These facts sug-
gest a potentially wide role for IDE in the clearance of
hormones and bioactive peptides. In addition to its role
in insulin catabolism, IDE has been found to degrade b-
amyloid (Ab) 40 and 42 and the amyloid precursor
protein (APP) intracellular domain and to eliminate
Ab42 neurotoxic effects [4]. The first evidence that IDE
might be involved in Ab42 degradation was found by
Kurochkin and Goto in 1994, who demonstrated that
purified rat IDE efficiently degrades synthetic Ab42 in
vitro [3]. Subsequently, it was shown that an IDE-like
activity from soluble and synaptic membrane fractions
of postmortem human brain both degrade Ab42 peptides
[5,6]; moreover, IDE doesn’t distinguish between endo-
genous and synthetic Ab42 as substrate in vitro [7]
The fact that extracellular Ab42 deposition is one of
the hallmarks of the neurodegenerative disorder Alzhei-
mer’s disease (AD) made IDE a promising candidate
involved in disease susceptibility. Several studies asso-
ciated linkage-peaks over the IDE region with late-onset
AD (LOAD) [8], age of onset in familial AD [9] and
high plasma Ab42 levels [10]. Furthermore, validated
linkage peaks with the metabolic syndrome Type 2
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region [11,12]. Fakhrai-Rad and colleagues narrowed
down the wide range of possible candidate genes to IDE
via transferring the gene from an inbred rat model of
T2DM to a normoglycemic rat, which resulted in the
recapitulation of several diabetic features, including
hyperinsulinemia and postprandial hyperglycemia [13].
In the present study, we undertook an attempt to
associate selected variants of the IDE gene with AD,
Ab42 plasma levels and T2DM in participants of the
Vienna Transdanube Aging (VITA) longitudinal cohort
study.
Methods
Subjects
Subjects of the present study were from the VITA study
which was described previously in greater detail [14,15].
The VITA study investigated the residents of two Vien-
nese districts born between May 1925 and June 1926 (i.
e., aged 75 years at inclusion). Data refer to the total
cohort at baseline recruitment of 606 individuals who
completed physical health check, questionnaires for edu-
cation, psychosocial activities and neuropsychological
examination. The 1
st follow-up after 30 months included
468 subjects performing the full health check at the
Danube hospital and 30 subjects that were either exam-
ined at home or interviewed on the phone. Further 70
subjects refused to attend the follow-up and 38
deceased. At the 2nd follow-up after 60 months 362
subjects attended the full health check at the Danube
hospital, whereas 68 subjects were visited at home or
only willing to take part in a telephone-interview, thus
providing only minimal information. 81 subjects out of
the 606 participants deceased between baseline and the
2nd follow-up investigation, 92 subjects refused to take
part again and in three cases no contact was possible to
establish. A diagnosis of AD was established applying
the NINCDS-ADRDA criteria [16]. All participants
passed through a consensus conference with regard to
t h ed i a g n o s e so fp o s s i b l eo rp r o b a b l eA D .T h ef i n a l
diagnosis was made by an experienced geronto-psychia-
trist. Since the NINCDS-ADRDA diagnosis requires
longitudinal information, at baseline all demented sub-
jects were considered as AD positive. In rare cases (n =
16), later (and thus more reliable) examinations revealed
“no AD” d i a g n o s e si ns u b j e c t sp r e v i o u s l yd i a g n o s e da s
AD positive. For the present analysis, these subjects
were treated as AD negative up to the last “no AD”
diagnosis. Additional information was obtained in all
cases for relevant serum parameters such as cortisol and
glucose level and T2DM was diagnosed according to the
guide line of the world health organisation. One partici-
pant was diagnosed with an untreated schizophrenia;
this subject was excluded from AD analyses, however
retained in T2DM analyses due to absence of anti-schi-
zophrenic medication, which is known to increase
T2DM susceptibility. Additional file 1 - “Demographic
information of the VITA study cohort” gives an over-
view of the subjects examined in this study.
The VITA study was carried out with the permission
of the Ethics Committee of the City of Vienna, Austria
and each participant gave a written informed consent.
DNA extraction
DNA was prepared from 2 ml EDTA-blood as pre-
viously described [15]. Finally, the DNA was aliquoted
into cryo-vials (NUNC, Langenselbold, Germany) and
stored frozen at -70 C till requirement.
IDE SNP selection and genotyping
The most validated IDE SNPS were selected after publi-
cation research for association studies in AD and T2DM
[17-20]. The IDE genotypes were determined using Taq-
Man assay with the real time PCR reaction using speci-
fic primers from TaqMan single nucleotide
polymorphism (SNP) Genotyping Assay (Applied Biosys-
tems, Darmstadt, Germany), which uses the 5’ nuclease
assay for amplifying and detecting specific SNP alleles in
purified genomic DNA samples. C_22272896_10 (IDE2,
rs4646953), C_27104906_10 (IDE7, rs2251101) and
C_12116624_10 (IDE9, rs1887922) assays were used for
SNP typing. Analysis of the genotypes was conducted
on the iCycler software with allelic discrimination pro-
gram (Bio-Rad, Munich, Germany).
Ab1-42 plasma level
Plasma levels of amyloid were determined by a double-
antibody sandwich enzyme-linked immunosorbent assay
method (Innogenetics NV, Ghent, Belgium). The
INNOTEST b-amyloid (1-42) allows the specific and
reliable measurement of (1-42) amyloid peptides in
plasma [21]. The detection range is 5-1000 pg/ml.
Statistical analysis
Prior to association analysis, IDE SNPs were tested for
Hardy-Weinberg equilibrium (HWE) with a one degree
of freedom c
2-test; no significant departures were
detected (all p-values > 0.001). Associations in the dif-
ferent time points were tested with logistic regression
when the outcome variable was binary (no/yes), or with
linear regression when influence on a continuous out-
come was examined. For longitudinal association analy-
sis, generalized estimating equations were used.
Genotypic associations were performed using three dif-
ferent models: in the additive model, each individual’s
risk allele count entered the regression; the dominant
model considered the presence of at least one risk allele
and in the recessive model, a genotypic risk was only
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allele. The Akaike Information Criterion (AIC) was used
to choose the best model. In single SNP analysis the
polymorphism’s minor allele was assumed to be the risk
allele; all minor allele frequencies were above our inclu-
sion threshold of 5%. In haplotype analysis, each haplo-
type allele was tested against all other alleles; to account
for phase uncertainty, each allele’s posterior probability
was incorporated into the model. Haplotypes were
defined with the expectation-maximization algorithm
[22]. Individuals with any missing values in IDE geno-
types (n = 38 of 606 in the original VITA cohort) were
removed from haplotype analyses. Only common haplo-
types with a frequency of at least 5% were analyzed.
Associations were considered to be significant at a =
0.05; due to the limited sample size of this study, the
reported nominal p-values were not adjusted for multi-
ple testing. Power estimates for the determined effect
sizes refer to the described analysis settings and result
from the comparison of test statistic distributions under
the null and alternative hypothesis. All association and
power analyses were performed in R version 2.10.0
using the packages geepack, pwr, powerMediation and
SimHap (all obtained from http://www.r-project.org).
Results
We examined the associations of IDE SNPs (IDE2,
rs4646953; IDE7, rs2251101; IDE9, rs1887922) and
derived haplotypes (on the coding strand in genomic
order 5’-IDE2-IDE9-IDE7-3’)w i t hA Da n dA b42
plasma levels, as well as with T2DM in unrelated sub-
jects participating in the VITA longitudinal cohort
study. Further information can be found in Additional
file 2 - “Insulin degrading enzyme genotype distribu-
tions and tests for Hardy-Weinberg equilibrium” and
Additional file 3 -"Power calculations for examined
markers and outcomes”.
Insulin degrading enzyme polymorphisms and Alzheimer’s
disease
Genetic associations of IDE with AD used dominant
models. In order to prove the independence of the
observed effects from known risk factors like presence
of APOE ε4 alleles and female sex, respectively, those
covariates were included in multivariate regressions.
This revealed a significant association of IDE2 (p = 0.03,
see Table 1) in subjects that attended the 60 months fol-
low-up (t = 60). The minor allele (C on the coding
strand) was found to have a protective effect (OR =
0.55); longitudinally, the effect size did not undergo sig-
nificant monotonic changes over time (p = 0.41, see
Table 1). Results from haplotype analysis reflect the
findings of single marker analysis in that the haplotype
that carries the IDE2 risk allele together with the major
alleles of IDE9 and IDE7 is also associated with AD at t
= 60 (see Table 2): haplotype CAA conveys a signifi-
cantly (p = 0.02) protective ( OR = 0.5) effect. As in sin-
gle marker analysis, the observed effect size did not
undergo significant monotonic changes over time (see
Table 2).
Insulin degrading enzyme polymorphisms and amyloid b42
plasma level
We then examined the additive influence of IDE SNP
alleles and haplotypes on the endophenotype Ab42
plasma level. Multivariate regressions included APOE ε4
Table 1 Association results of insulin degrading enzyme SNPs
AD Ab42 plasma level [pg/ml] T2DM
Polymorphism (major/minor allele) focus OR (95% CI) p-value slope (95% CI) p-value OR (95% CI) p-value
IDE2 (T/C) baseline - - 22.36 (8.08 - 36.6) 0.002 0.82 (0.23 - 2.86) 0.75
IDE2 (T/C) 1
st follow-up 0.66 (0.36 - 1.21) 0.18 21.04 (2.08 - 40) 0.03 0.96 (0.3 - 3.05) 0.95
IDE2 (T/C) 2
nd follow-up 0.55 (0.32 - 0.95) 0.03 35.26 (12.8 -57.8) 0.002 1.32 (0.41 - 4.24) 0.64
IDE2 (T/C) × examination longitudinal 1.13 (0.84 - 1.43) 0.41 8.23 (1.93 -14.5) 0.01 1.27 (0.81 - 1.73) 0.31
IDE7 (A/G) baseline 1.74 (0.63 - 4.78) 0.28 -5.24 (-16.7 - 6.2) 0.37 2.4 (1.25 - 4.63) 0.009
IDE7 (A/G) 1
st follow-up 1.26 (0.77 - 2.07) 0.35 -5.31 (-21 -10.3) 0.51 2.62 (1.32 - 5.18) 0.006
IDE7 (A/G) 2
nd follow-up 0.97 (0.62 - 1.52) 0.89 -14.27 (-33.7 - 5.2) 0.15 3.47 (1.72 - 6.97) 0.0005
IDE7 (A/G) × examination longitudinal 0.86 (0.56 - 1.16) 0.33 -3.37 (-8.2 - 1.49) 0.18 1.1 (0.91 - 1.3) 0.32
IDE9 (A/G) baseline 1.87 (0.71 - 4.92) 0.21 -7.36 (-19.5 - 4.8) 0.24 1.65 (0.72 - 3.79) 0.24
IDE9 (A/G) 1
st follow-up 1.02 (0.62 - 1.69) 0.94 -8.39 (-24.9 - 8.1) 0.32 1.17 (0.46 - 3.0) 0.75
IDE9 (A/G) 2
nd follow-up 0.99 (0.62 - 1.58) 0.96 -11.1 (-31.8 - 9.7) 0.3 1.75 (0.7 - 4.37) 0.23
IDE9 (A/G)× examination longitudinal 0.88 (0.57 - 1.19) 0.42 -0.85 (-5.5 - 3.83) 0.72 0.98 (0.78- 1.17) 0.81
Insulin degrading enzyme (IDE) SNPs (IDE2, rs4646953; IDE7, rs2251101; IDE9, rs1887922) were associated with Alzheimer’s disease (AD), amyloid b42 (Ab42) plasma
levels and Type 2 diabetes mellitus (T2DM). Effect sizes and nominal p-values were derived from multivariate regression analysis with sex and presence of
apolipoprotein E (APOE ε4) alleles as covariates in regressions on AD affection and Ab42 plasma level, respectively. T2DM affection as outcome used sex and BMI
as covariates. Longitudinal analysis examined interactions of all covariates with the examination (baseline, 1
st and 2
nd follow-up). Associations were calculated
using dominant models for AD, additive models for Ab42 plasma level and recessive models for T2DM. Nominally significant p-values (p < 0.05) are shown in
bold.
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revealed that with each minor C allele of IDE2 the Ab42
plasma level increases between 21.04 and 35.26 pg/ml,
depending on time point of analysis (see Table 1 and
Figure 1A). This finding was significant in all time
points (see Table 1). Longitudinal analysis revealed that
the observed effect significantly (p = 0.01) increased
with each follow-up by 8.23 pg/ml (see Table 1). Of
note, an increase in Ab42 plasma level was not exclusive
to IDE2 risk allele carriers, but was also observed in
individuals homozygous for the major allele (see Table 3
and Figure 1). Since an increased Ab42 plasma level is a
known risk factor for AD, we also examined the interac-
tion of the IDE2 genotype with the AD disease status on
the Ab42 plasma level. The effect sizes at t = 30 and t =
60 reveal that the IDE2 C allele as well as AD affection
both lead to an increased Ab42 plasma level, however
that the combined effect is much more pronounced
than the sum of both effects (see Table 4 and see Figure
1B). However, the effects for AD and its interaction
with the IDE2 genotype are only significant at t = 60,
while the effect of IDE2 alone reaches only marginal sig-
nificance (see Table 4). On multimarker level, we found
each CAA haplotype to significantly increase the Ab42
plasma level between 25.93 and 41.5pg/ml, depending
on time point of analysis (see table 3B). Longitudinally,
we observed no increasing haplotype effect on Ab42
plasma level between examinations (see Table 2).
Insulin degrading enzyme polymorphisms and type 2
diabetes mellitus
Genetic associations of IDE with T2DM used recessive
models. In order to prove the independence of the
observed effects from known risk factors like body mass
index (BMI) and female sex, those covariates were
included in multivariate regressions. In all three time
points, we found the minor G allele of IDE7 to bear a
significant (p<0.01) genotypic risk to develop T2DM,
with an initial (t = 0) OR of 2.4, that continually
increased slightly (OR = 1.1) but not significantly (p =
0.32) to 3.47 at t = 60 (see Table 1). Haplotype analyses
revealed the association of haplotypes TAG and TGG
w i t hT 2 D M ,i nc a s eo ft h ef i r s ti na l lt h r e et i m ep o i n t s ,
in case of the second only at t = 0 and t = 60 (see Table
2). In line with the single marker result for IDE7, both
haplotypes convey a genetic risk to become diabetic
with significant effect sizes ranging from 3.25 to 3.28 for
TGG and from 6 to even 13 for TAG, depending on
Table 2 Association results of insulin degrading enzyme haplotypes
haplotype AD Ab42 plasma level [pg/ml] T2DM
5’ IDE2 IDE9 ’3 IDE7 focus OR (95% CI) p-value Slope (95% CI) p-value OR (95% CI) p-value
T A A baseline 2.01 (0.46 -9.47) 0.34 -5.8 (-16.1 - 4.5) 0.27 1.01 (0.63 -1.61) 0.98
TAA 1
st follow-up 1.96 (0.98 - 3.9) 0.06 -5.33 (-19.5- 8.86) 0.46 0.83 (0.5 - 1.38) 0.46
TAA 2
nd follow-up 1.51 (0.85 -2.68) 0.16 -7.37 (-24.7 -9.95) 0.41 0.92 (0.54 -1.59) 0.78
TA
× examination
A longitudinal 0.94 (0.63 -1.41) 0.77 -0.05 (-0.18- 0.07) 0.4 0.95 (0.84 -1.07) 0.41
T G G baseline 2.23 (0.82 -6.1) 0.12 -6.98 (-20.4- 6.47) 0.31 3.25 (1.31 -8.04) 0.01
TGG 1
st follow-up 1.03 (0.61 -1.74) 0.92 -6.78 (-25.1-11.6) 0.47 2.22 (0.81- 6.05) 0.12
TGG 2
nd follow-up 0.93 (0.56 -1.53) 0.78 -12.06 (-35.3-1.17) 0.31 3.28 (1.2 - 8.99) 0.02
TG
× examination
G longitudinal 0.82 (0.59 -1.14) 0.25 -0.01 (-0.23- 0.21) 0.92 0.99 (0.79 -1.24) 0.93
T A G baseline 0.91 (0.25 -3.26) 0.89 -0.62 (-17.9-16.7) 0.94 6.0 (1.29 -27.7) 0.02
TAG 1
st follow-up 1.22 (0.66 -2.26) 0.52 -0.75 (-25.13-23.6) 0.95 13.0 (1.47-129.33) 0.02
TAG 2
nd follow-up 1.02 (0.57-1.83) 0.94 -13.76 (-43-15.48) 0.36 8.66 (1.54 -48.77) 0.01
TA
× examination
G longitudinal 0,99 (0.69- 1.43) 0.97 0.24 (-0.45- 0.94) 0.49 1.28 (0.64 - 2.6) 0.49
C A A baseline - - 26.36 (10.84-41.88) 0.001 0.34 (0.04 -2.63) 0.3
CAA 1
st follow-up 0.65 (0.34-1.23) 0.18 25.93 (5.21-46.64) 0.01 0.59 (0.12 -2.82) 0.51
CAA 2
nd follow-up 0.5 (0.28- 0.88) 0.02 41.5 (17 - 66) 0.001 0.87 (0.18- 4.14) 0.86
CA
× examination
A longitudinal 1.08 (0.81-1.46) 0.59 0.23 (-0.38 -0.86) 0.45 1.26 (0.69 -2.32) 0.45
Insulin degrading enzyme (IDE) haplotypes (IDE2, rs4646953; IDE7, rs2251101; IDE9, rs1887922) with frequencies > 5% were associated with Alzheimer’s disease
(AD), amyloid b42 (Ab42) plasma levels and Type 2 diabetes mellitus (T2DM). Effect sizes and nominal p-values were derived from multivariate regression analysis
with sex and presence of apolipoprotein E (APOE ε4) alleles as covariates in regressions on AD affection and Ab42 plasma level, respectively. T2DM affection as
outcome used sex and BMI as covariates. Longitudinal analysis examined interactions of all covariates with the examination (baseline, 1
st and 2
nd follow-up).
Associations were calculated using dominant models for AD, additive models for Ab42 plasma level and recessive models for T2DM. Nominally significant p-
values (p < 0.05) are shown in bold.
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associated haplotypes did not exhibit significant mono-
tonic changes in effect sizes (see Table 2).
Discussion
The identification of a late-onset AD risk locus on chro-
mosome 10q which also affects plasma Ab42 levels, has
led to the search for functional candidates in this region
[8,10]. Because of its mapping to the AD linkage peak
and of the ability of its gene product to degrade Ab42,
IDE was proposed to harbour a plausible origin for the
observed effects. Since IDE is also well-known to be
associated with increased risk for T2DM [12,23,24], the
present study aimed at examining the effects of selected
common IDE polymorphisms on both disease outcomes
Figure 1 Amyloid b42 (Ab42) plasma levels [pg/ml]. A) in insulin degrading enzyme IDE2 SNP (rs4646953) genotypes and B) in IDE2
genotypes stratified by Alzheimer’s disease (AD) status (AD no/yes) at baseline, 1
st and 2
nd follow-ups.
Table 3 Longitudinal analysis of amyloid b42 (Ab42)
plasma levels in different insulin degrading enzyme 2
(SNP rs4646953) genotypes
IDE2 genotype Ab42 plasma level [pg/ml]
slope (95% CI) p-value
all genotypes 23.7 (20.34 - 27.07) < 2 ∙ 10
only T/T 21.33 (17.73 - 24.94) < 2 ∙ 10
-16
only T/C 25.84 (16.52 - 35.17) 5.6 ∙ 10
-8
only C/C 43.28 (27.7 - 58.86) 5.23 ∙ 10
-8
Effect sizes and nominal p-values were derived from multivariate regression
analysis with sex and presence of apolipoprotein E (APOE ε4) alleles as
covariates. All IDE2 (SNP rs4646953) genotype groups display a highly
significant increase in Ab42plasma concentration between each of the three
examinations.
Table 4 Interaction analysis of insulin degrading enzyme
2 (SNP rs4646953) genotype
parameter (baseline/
risk)
examination slope (95% CI) p-
value
IDE2 (T/C) baseline 20.72 (6.23 - 35.21) 0.005
AD (no/yes) -7.45 (-50.34 - 35.45) 0.73
IDE2 × AD - -
IDE2 (T/C) 1
st follow-up 13.60 (-6.92 - 34.11) 0.19
AD (no/yes) 7.36 (-23.75 - 38.48) 0.64
IDE2 × AD 33.91 (-22.02 -
89.84)
0.24
IDE2 (T/C) 2
nd follow-
up
21.41 (-3.43 - 46.25) 0.09
AD (no/yes) 36.27 (3.72 - 68.82) 0.03
IDE2 × AD 76.89 (24.01 -
129.77)
0.005
Analysis of interaction of insulin degrading enzyme SNP rs4646953 (IDE2)
genotype and Alzheimer’s disease (AD) status on amyloid b42 (Ab42) plasma
level is shown. Effect sizes and nominal p-values were derived from
multivariate regression analysis with sex and presence of apolipoprotein E
(APOE ε4) alleles as covariates. Nominally significant p-values (p < 0.05) are
shown in bold.
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pating in the longitudinal VITA cohort study. The ana-
lyzed polymorphisms should serve as proxies to partly
capture the common allelic variation in the up- (IDE2)
and downstream (IDE7) region, as well as in the gene
body (IDE9) of IDE. Our finding that we were not able
to detect associations of IDE9 with neither examined
trait leads us to the hypothesis that common IDE var-
iants influencing the primary structure of the IDE pro-
tein (i.e. non-synonymous SNPs and those affecting
splicing junctions, respectively) may have no major
impact on AD and T2DM susceptibility. However,
despite extended linkage disequilibrium (LD) in the IDE
region (see Additional file 4 - “Linkage disequilibrium in
the insulin degrading enzyme region”), a single SNP may
not fully represent the allelic variation throughout the
gene. In fact, 13 tag SNPs of 45 SNPs genotyped in the
HapMap CEU panel (release 24) are needed to capture
the variation inside IDE with a mean r
2 of 0.99 (data
not shown). Therefore the possibility remains that dele-
terious variants not in LD with IDE9 exist, e.g. rare IDE
variants with possibly large effects on our examined
traits. While this remains speculative, we found that
allelic variation at opposing ends of IDE is associated
with different outcomes: the upstream and 5’-untrans-
lated region (UTR) harbours polymorphisms presumably
modifying the AD disease risk and the Ab42 plasma
level, whereas 3’-UTR and downstream variants may
trigger T2DM susceptibility.
There is evidence that the IDE level and therefore
Ab42 degrading activity is lower in AD brains than in
those of unaffected subjects [6], which can be also an
effect of oxidative stress (OS). OS is considered to be a
key mechanism in the pathophysiology of AD and is
characterized by increased highly reactive oxygen species
(ROS) production and decreased antioxidant defence
[25,26]. Interestingly the catalytic activity of IDE is
reduced through ROS and also the enzymatic activity
toward Ab hydrolysis is decreased [27]. Nonetheless,
this has to be further investigated, as it might provide
additional link between AD and T2DM. Furthermore,
s t u d i e so np r o - o x i d a n t sc o u ld be equally important in
order to develop new treatment avenues for AD.
A recent study of Zuo and Jia found that variants in
the proximal IDE promoter increase transcription and
thus provide a possible mechanism explaining the pro-
tective effect on AD susceptibility found for the exam-
ined polymorphisms [28]. Among those, IDE2
overlapped with our study, however with different
results: while we found an association with AD in our
Vienna-based cohort, IDE2 was not associated in the
mentioned Han Chinese sample. This reflects the situa-
tion in AlzGene meta-analyses, which list a slightly pro-
tective odds ratio (OR) of 0.93 for IDE2 in Central
European study populations and an overall OR of 1.0 (i.
e. no effect) if Asian studies are included [29]. This
makes clear that IDE2 is unlikely to be the causal var-
iant and furthermore raises the possibility that LD
between IDE2 and the presumed functional allele varies
between Central European and Asian populations. Given
this, our present study and that of Zuo and Jia [28]
agree that promoter variants leading to increased IDE
transcription protect against AD. Correspondingly, one
would expect Ab42 plasma levels to be lower in indivi-
duals carrying high expression variants, but intriguingly
our results show the opposite (see Table 1 and 2). This
contradicts the results from a recent study which found
high IDE expression variants to be correlated with lower
Ab plasma levels, however, Ab40 contributed more to
the observation than Ab42 [30]. Plasma Ab42 levels are
thus not reliably predicted by IDE polymorphisms alone,
because also trans-acting variants were shown to influ-
ence the expression of IDE [31]. Furthermore, due to
the wide range of IDE substrates, an important determi-
nant for Ab42 degrading activity is the concentration of
the primary IDE target (i.e. insulin), illustrated by the
finding that even Ab40 clearance is effectively inhibited
by insulin [32]. This notion is supported by our observa-
tion that a large proportion of the Ab42 plasma level is
explained by factors different from the IDE promoter
genotype (see Table 4).
Hallmarks of T2DM are the presence of insulin resis-
tance and insulin receptor insensitivities. Insulin resis-
tance precedes the onset of T2DM for years [33] and
results in compensatory hyperinsulinemia, which is the
first step to developing T2DM [34]. Limited capacities
to degrade increased plasma insulin levels contribute to
development of T2DM. Our association of the down-
stream variant IDE7 with T2DM might be an indirect
signal that extends from the IDE 3’-UTR over LD. The
presumed risk allele may attenuate translation or reduce
the stability of the IDE mRNA, thus challenging IDE
activity and promoting hyperinsulinemia, explaining the
increased T2DM susceptibility.
Based on these assumptions, we delineate the model
that polymorphisms at opposing ends of the IDE gene
may lead to expression changes with consequences on
susceptibility to different diseases: promoter variation
presumably increases IDE expression and protects from
AD, while 3’-UTR variation is assumed to decrease IDE
expression and to increase T2DM risk. Correspondingly,
haplotypes that carry both associated alleles on a single
DNA molecule (5’-CGG-3’ and 5’-CAG-3’) should reveal
a balanced (i.e. no) effect on AD and T2DM. Due to the
low frequencies of these haplotypes (0.5% and 0.2%, data
not shown) in the VITA study cohort, we were however
not able to reliably examine this balancing effect.
Despite the plausibility of the model in the context of
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requires further examinations, including the determina-
tion of the IDE activity, which is expected to provide
deeper insight into disease causing mechanisms [35].
Conclusions
Based on our SNP and haplotype results, we delineate
the model that IDE promoter and 3’-UTR/downstream
variation may have opposing effects on IDE expression,
which is assumed to be a relevant endophenotype with
disorder-specific effects on AD and T2DM susceptibility.
As a starting point for targeted investigations, the pre-
sent study provides insight how variation in the IDE
gene contributes to link the pathophysiologically differ-
ent diseases AD and T2DM.
Additional material
Additional file 1: Demographic information of the VITA study
cohort. Abbreviations used: AD = Alzheimer’s disease; BMI = body mass
index; SD = standard deviation; T2DM = Type 2 diabetes mellitus.
Additional file 2: Insulin degrading enzyme genotype distributions
and tests for Hardy-Weinberg equilibrium. Insulin degrading enzyme
(IDE) genotype distributions and tests for Hardy-Weinberg equilibrium
(HWE) in analysis subgroups defined by cross-sectional outcomes. No
significant departures from HWE were detected (all p > 0.001).
Additional file 3: Power calculations for examined markers and
outcomes. The presented additional file 3 indicate the power to find
nominally significant associations (p < 0.05) given analysis settings used
for the estimation of effect sizes shown in Tables 1 and 2. Abbreviations
used: Ab42 = amyloid beta 1-42 plasma concentration; AD = Alzheimer’s
disease; IDE2 = rs4646953; IDE7 = rs2251101; IDE9 = rs1887922; SNP =
single nucleotide polymorphism.
Additional file 4: Linkage disequilibrium in the insulin degrading
enzyme region. Linkage disequilibrium (LD) in the IDE gene region ± 10
kb is shown based on D’ values between single nucleotide
polymorphisms (SNPs) genotyped in the HapMap CEU panel (release 24).
LD colour scheme corresponds to default settings used in Haploview.
Positions of SNPs examined in the present study are indicated in blue. Of
note, rs4646953 (IDE2) has not been genotyped in the HapMap project,
therefore no LD information is available for this SNP.
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